APP C-Terminal Fragment: Effect on Cognition and Aβ
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2017 - September 30, 2020
Grant ID
A2017443S
Goals
For the past two decades, researchers in Alzheimer’s disease (AD) field have focused on the neurotoxicity associated with Aβ peptide production and accumulation. Amyloid beta (Aβ) is a small peptide molecule generated from cleavage of amyloid precursor protein (APP). Our proposed studies will explore the APP molecule as a whole cellular component that could affect brain function and memory processing. We will focus more specifically on the intracellular fragment of APP that could initiate signaling events. We aim to deliver a small peptide fragment to the brain of familial AD mouse models using a viral strategy. The overall goal is to develop novel rational therapeutics aimed at preserving cognitive function and reducing Aβ burden in those suffering from AD.
Summary
Our research will test the hypothesis that production of an intracellular fragment originating from APP could rescue memory decline in AD mice. Viral injection in the brain will facilitate the overproduction of this fragment. We will consider the likelihood that viral transduction of this short peptide could attenuate Aβ production and deposition in AD mice, and rescue their memory function. We will characterize the mechanisms underlying these changes.
Grantee institution at the time of this grant: University of Chicago
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD